Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-month, Multicenter, Randomized, Open-label Study to Investigate Efficacy and Safety of Concentration Controlled Everolimus With Reduced Dose Cyclosporine A Versus Mycophenolate Mofetil With Standard Dose Cyclosporine A in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
Brief Summary: The 12 Month Core Study (CRAD001A1202) was designed to evaluate the efficacy and safety comparing concentration-controlled everolimus (1.5 mg/day starting dose) with reduced dose cyclosporine and corticosteroids versus 2 g/day mycophenolate mofetil (MMF) with standard dose cyclosporine and corticosteroids in de novo renal transplant recipients.

Extension Study (CRAD001A1202E1): Until 24 months after renal transplantation, the study was designed to evaluate the long-term safety and efficacy comparing concentration-controlled everolimus with reduced dose cyclosporine (Neoral®) and corticosteroids versus mycophenolate mofetil with standard dose Neoral® and corticosteroids in de novo renal transplant recipients. Beyond 24 months after renal transplantation, the study was designed to provide everolimus treatment for patients in everolimus group until everolimus is approved and marketed in Japan.


Options:
A: Arm Label: Everolimus + Reduced dose of cyclosporine; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Basiliximab, Drug: Cyclosporine A, Drug: Corticosteroid | Arm Label: Mycophenolate mofetil (MMF) + Standard dose of cyclosporine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate mofetil (MMF), Drug: Basiliximab, Drug: Cyclosporine A, Drug: Corticosteroid | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine | Intervention Type: DRUG; Name: Mycophenolate mofetil (MMF); Assigned to Arm(s): Mycophenolate mofetil (MMF) + Standard dose of cyclosporine | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine, Mycophenolate mofetil (MMF) + Standard dose of cyclosporine | Intervention Type: DRUG; Name: Cyclosporine A; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine, Mycophenolate mofetil (MMF) + Standard dose of cyclosporine | Intervention Type: DRUG; Name: Corticosteroid; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine, Mycophenolate mofetil (MMF) + Standard dose of cyclosporine
B: Arm Label: Calcineurin free; Type: EXPERIMENTAL; Interventions: Drug: Sirolimus, Drug: Prednisone, Drug: Mycophenolate mofetil, Procedure: Protocol biopsies | Arm Label: Calcineurin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporine A, Drug: Prednisone, Drug: Mycophenolate mofetil, Procedure: Protocol biopsies | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): Calcineurin free | Intervention Type: DRUG; Name: Cyclosporine A; Assigned to Arm(s): Calcineurin | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Calcineurin, Calcineurin free | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Calcineurin, Calcineurin free | Intervention Type: PROCEDURE; Name: Protocol biopsies; Assigned to Arm(s): Calcineurin, Calcineurin free
C: Arm Label: Everolimus + Low dose CsA +PD; Type: EXPERIMENTAL; Interventions: Drug: Everolimus + Low dose CsA +PD | Arm Label: Myfortic+ Standard CsA + PD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Myfortic+ Standard CsA + PD | Intervention Type: DRUG; Name: Everolimus + Low dose CsA +PD; Assigned to Arm(s): Everolimus + Low dose CsA +PD | Intervention Type: DRUG; Name: Myfortic+ Standard CsA + PD; Assigned to Arm(s): Myfortic+ Standard CsA + PD
D: Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): N/A

Answer: A